The use of a monotherapy against either PD-1/PD-L1 or CTLA-4/CD80 may apply a positive selection pressure to a tumor, resulting in the outgrowth of clones that are able to modulate other immune checkpoints. The gene discussed is CD274; the disease is neoplasm.